Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för eliglustat tartrate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

10 träffar

Bibliografisk träff 2015-01-01

Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy.

Pavlova EV, Archer J, Wang S, Dekker N, Aerts JM, Karlsson S, Cox TM.

J Pathol · research support, non-u.s. gov't; journal article · DOI 10.1002/path.4452

Bibliografisk träff 2014-10-01

Eliglustat: first global approval.

Poole RM.

Drugs · review; journal article · DOI 10.1007/s40265-014-0296-3

Bibliografisk träff 2013-09-01

Gaucher disease and its treatment options.

Bennett LL, Mohan D.

Ann Pharmacother · review; journal article · DOI 10.1177/1060028013500469

Bibliografisk träff 2013-01-01

The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?

Shayman JA.

Trans Am Clin Climatol Assoc · research-article; review; journal article; research support, n.i.h., extramural

Bibliografisk träff 2010-10-01

Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.

Cox TM.

Curr Opin Investig Drugs · research support, non-u.s. gov't; review; journal article

Bibliografisk träff 2010-09-23

Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.

Peterschmitt MJ, Burke A, Blankstein L, Smith SE, Puga AC, Kramer WG, Harris JA, Mathews D, Bonate PL.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1177/0091270010372387

Bibliografisk träff 2010-08-16

Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.

Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI, Kaper M, Singh T, Puga AC, Peterschmitt MJ.

Blood · clinical trial, phase ii; brief-report; research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2010-06-293902

Bibliografisk träff 2010-08-01

ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.

Shayman JA.

Drugs Future · research-article; journal article · DOI 10.1358/dof.2010.035.08.1505566

Bibliografisk träff 2010-05-03

A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ.

Blood · clinical trial, phase ii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/blood-2010-03-273151

Bibliografisk träff 2007-05-16

A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.

McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J.

Mol Genet Metab · journal article · DOI 10.1016/j.ymgme.2007.04.001